Sk Biopharmaceutica (Korea) Investor Sentiment

326030 Stock   102,100  1,500  1.45%   
About 61% of Sk Biopharmaceutica's investor base is looking to short. The analysis of current outlook of investing in Sk Biopharmaceuticals Co suggests that many traders are alarmed regarding Sk Biopharmaceutica's prospects. The current market sentiment, together with Sk Biopharmaceutica's historical and current headlines, can help investors time the market. In addition, many technical investors use Sk Biopharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
over a month ago at news.google.com         
Korea Investment Securities raised its target stock price to 145,000 won from 130,000 won on t.. -
Google News at Macroaxis
over a month ago at news.google.com         
SK biopharm swings to profit in Q3 on strong cenobamate sales -
Google News at Macroaxis
over a month ago at news.google.com         
3 Prominent Stocks Estimated To Be Up To 46 percent Below Intrinsic Value - Yahoo Finance
Google News at Macroaxis
over three months ago at news.google.com         
On September 20, SK Biopharmaceuticals is strong. SK Biopharmaceuticals closed at 105,800 w.. -
Google News at Macroaxis
over three months ago at news.google.com         
SK Biopharmaceuticals Co., Ltd.s largest shareholders are public companies who were rewarded as mark...
Google News at Macroaxis
over three months ago at news.google.com         
SK Biopharmaceuticals Co., Ltd. Looks Just Right With A 25 percent Price Jump - Simply Wall St
Google News at Macroaxis
over three months ago at news.google.com         
SK Biopharmaceuticals swings to net profit in Q2 - MSN
Google News at Macroaxis
over three months ago at news.google.com         
SK Biopharmaceuticals swings to net profit in Q2 - Yonhap News Agency
Google News at Macroaxis
over three months ago at news.google.com         
Korean Air sees record sales in Q2, SK Biopharm turns profitable -
Google News at Macroaxis
over three months ago at news.google.com         
Endo Announces Agreement for Paladin Labs to Commercialize SK Biopharmaceuticals XCOPRI in Canada - ...
Google News at Macroaxis
over three months ago at news.google.com         
Exploring Undervalued Stocks On KRX With Intrinsic Value Discounts Ranging From 12.7 percent To 46.1...
Google News at Macroaxis
over six months ago at news.google.com         
Public companies are SK Biopharmaceuticals Co., Ltd.s biggest owners and were hit after market cap ....
Google News at Macroaxis
over six months ago at news.google.com         
Reasons to Add Veeva Systems Stock to Your Portfolio - Yahoo Finance UK
Google News at Macroaxis
over six months ago at news.google.com         
SK Biopharmaceuticals shifts to black in Q1 - MSN
Google News at Macroaxis
over six months ago at news.google.com         
SK Biopharmaceuticals Co., Ltd. Not Lagging Industry On Growth Or Pricing - Simply Wall St
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Sk Biopharmaceutica that are available to investors today. That information is available publicly through 326030 media outlets and privately through word of mouth or via 326030 internal channels. However, regardless of the origin, that massive amount of 326030 data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Sk Biopharmaceutica news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Sk Biopharmaceutica relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Sk Biopharmaceutica's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Sk Biopharmaceutica alpha.

Sk Biopharmaceutica Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for 326030 Stock analysis

When running Sk Biopharmaceutica's price analysis, check to measure Sk Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sk Biopharmaceutica is operating at the current time. Most of Sk Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Sk Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sk Biopharmaceutica's price. Additionally, you may evaluate how the addition of Sk Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated